Art. -Nr.: HY-109104

Copy Link Print Information

Telratolimod

(Synonyms: MEDI9197; 3M-052)

10 Cited Publications

Kundenbewertung

Based on 10 publication(s) in Google Scholar

Telratolimod (MEDI9197) is a potent toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.44%
CAS. Nr.: 1359993-59-1
Formel: C₃₆H₅₉N₅O₂
Molecular Weight:593.89

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Telratolimod Chemical Structure

CAS. Nr.: 1359993-59-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (10)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

Telratolimod (MEDI9197) is a potent toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity^[1].

IC₅₀ & Target

TLR7

TLR8

Alle Toll-like Receptor (TLR) Isoform-spezifische Produkte anzeigen :

In Vitro

Telratolimod (3M-052) is a toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Telratolimod (50 μg) inhibits the tumor volume, and more potently blocks tumor gowth in combination with CpG ODN in BALB/c mice bearing CT26 colon carcinoma cells. Telratolimod (100 μg) plus 200 μg of CpG ODN slows tumor growth and prolongs survival of mice bearing large tumors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1359993-59-1
Appearance Solid
Molecular Weight 593.89
Formel C₃₆H₅₉N₅O₂
Color White to light yellow
SMILES

NC1=NC2=CC=CC=C2C3=C1N=C(CCCC)N3OCCCCNC(CCCCCCCCCCCCCCCCC)=O
Synonyms

MEDI9197; 3M-052
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (10)

All Bio/Physico-chemical AssayELISACell Imaging/StainingIF

Sort by:

Journal Impact Factor

ACS Nano

Nanocarrier Co-formulation for Delivery of a TLR7 Agonist plus an Immunogenic Cell Death Stimulus Triggers Effective Pancreatic Cancer Chemo-immunotherapy. [Abstract]

2022 Aug 23;16(8):13168-13182. PMID: 35920660
Adv Sci (Weinh)

KRAS mRNA Spleen-Targeting Lipid Nanoparticles Synergize with Irinotecan Silicasomes to Robustly Augment the Cancer Immunity Cycle in Pancreatic Cancer. [Abstract]

2025 Jun 11:e04886. PMID: 40498983
Adv Sci (Weinh)

Adipocytes Encapsulating Telratolimod Recruit and Polarize Tumor-Associated Macrophages for Cancer Immunotherapy. [Abstract]

2023 Feb;10(5):e2206001. PMID: 36526596

Telratolimod purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 Feb;10(5):e2206001. [Abstract]

Telratolimod (0.2 mg/kg; intratumorally injection; single daily for 3 days) or Telratolimod loaded into the lipid droplets of adipocytes significantly inhibit growth of both original and distant tumor in vivo.
J Nanobiotechnology

A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune. [Abstract]

2024 May 29;22(1):296. PMID: 38811964

Telratolimod purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 May 29;22(1):296. [Abstract]

UV-vis spectra of 3M-052 (Telratolimod), CM, UiO-66, NHWD-870, MCM@UN.

Telratolimod purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 May 29;22(1):296. [Abstract]

Insertion of the immunostimulant (3M-052 (Telratolimod)) into the lipid bilayer of cancer cell membranes through the lipid tail of 18 C. (Dil labeled cell membrane, FITC labeled 3M-052).
J Immunother Cancer

In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8+ T cell responses. [Abstract]

2025 Dec 12;13(12):e011665. PMID: 41386973
ACS Cent Sci

Tumor Cell-Surface Binding of Immune Stimulating Polymeric Glyco-Adjuvant via Cysteine-Reactive Pyridyl Disulfide Promotes Antitumor Immunity. [Abstract]

2022 Oct 26;8(10):1435-1446. PMID: 36313164

Telratolimod purchased from MedChemExpress. Usage Cited in: ACS Cent Sci. 2022 Oct 26;8(10):1435-1446. [Abstract]

MC38 tumor-bearing mice were injected intratumorally with p(Man-TLR7-PDS), control TLR7/8 agonist 3M-052 (Telratolimod), or PBS. Six hours after injection, sera were collected and analyzed for proinflammatory cytokines, including IFNγ, IL-6, MCP-1, IFNβ and IL-27.
JCI Insight

Coimmunomodulation of tumor and tumor-draining lymph nodes during in situ vaccination promotes antitumor immunity. [Abstract]

2022 May 17;e146608. PMID: 35579961

Telratolimod purchased from MedChemExpress. Usage Cited in: JCI Insight. 2022 May 17;e146608. [Abstract]

Representative images of solutions containing micellar MEDI9197 before and after filtration. The numbers indicate molar ratio of MEDI9197 to DSPE-PEG-2000.

Telratolimod purchased from MedChemExpress. Usage Cited in: JCI Insight. 2022 May 17;e146608. [Abstract]

Loading efficacy of MEDI9197 (Telratolimod, 30-300 μg) at various molar ratios of MEDI9197 to DSPE-PEG-2000 (n = 4).
Front Public Health

SARS-CoV-2 delta (B.1.617.2) spike protein adjuvanted with Alum-3M-052 enhances antibody production and neutralization ability. [Abstract]

2023 Jan 6:10:976686. PMID: 36684881
Biochem Biophys Res Commun

Anti-TNFR2 enhanced the antitumor activity of a new HMGN1/3M-052 stimulated dendritic cell vaccine in a mouse model of colon cancer. [Abstract]

2023 Apr 23:653:106-114. PMID: 36868074
Patent

US20200316211A1.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 62.5 mg/mL (105.24 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 50 mg/mL (84.19 mM; ultrasonic and warming and heat to 60°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6838 mL

8.4191 mL

16.8381 mL

5 mM

0.3368 mL

1.6838 mL

3.3676 mL

10 mM

0.1684 mL

0.8419 mL

1.6838 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.21 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (3.50 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (3.50 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 4

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (268 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhao BG, et al. Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors. J Immunother Cancer. 2014 May 13;2:12. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	1.6838 mL	8.4191 mL	16.8381 mL	42.0953 mL
	5 mM	0.3368 mL	1.6838 mL	3.3676 mL	8.4191 mL
	10 mM	0.1684 mL	0.8419 mL	1.6838 mL	4.2095 mL
	15 mM	0.1123 mL	0.5613 mL	1.1225 mL	2.8064 mL
	20 mM	0.0842 mL	0.4210 mL	0.8419 mL	2.1048 mL
	25 mM	0.0674 mL	0.3368 mL	0.6735 mL	1.6838 mL
	30 mM	0.0561 mL	0.2806 mL	0.5613 mL	1.4032 mL
	40 mM	0.0421 mL	0.2105 mL	0.4210 mL	1.0524 mL
	50 mM	0.0337 mL	0.1684 mL	0.3368 mL	0.8419 mL
	60 mM	0.0281 mL	0.1403 mL	0.2806 mL	0.7016 mL
	80 mM	0.0210 mL	0.1052 mL	0.2105 mL	0.5262 mL
DMSO	100 mM	0.0168 mL	0.0842 mL	0.1684 mL	0.4210 mL

Keywords

Telratolimod

10 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Telratolimod

MCE Bioactive Compound Library

Clinical Compound Library Plus

Publications Citing Use of MedChemExpress (MCE) Telratolimod

Alle Toll-like Receptor (TLR) Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (10)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Telratolimod

MCE Bioactive Compound Library

Clinical Compound Library Plus

Publications Citing Use of MedChemExpress (MCE) Telratolimod

Alle Toll-like Receptor (TLR) Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (10)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Telratolimod Related Classifications

Art. -Nr.: HY-109104